

Antibiotics, Topical Review

03/05/2010

Copyright © 2007 - 2010 by Provider Synergies, L.L.C. All rights reserved.
Printed in the United States of America.

All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage and retrieval system without the express written consent of Provider Synergies, L.L.C.

All requests for permission should be mailed to:

*Attention: Copyright Administrator
Intellectual Property Department
Provider Synergies, L.L.C.
10101 Alliance Rd. Ste 201
Cincinnati, Ohio 45242*

The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to PSTCReDitor@magellanhealth.com.



Together, we can do more.

Antibiotics, Topical Review

FDA-Approved Indications^{1,2,3,4}

| Drug | Manufacturer | Indication(s) |
|--|-----------------|--|
| bacitracin ointment | generic | Prevention of skin and skin structure infections after a minor compromise in skin integrity such as minor burns or skin abrasion |
| bacitracin zinc ointment | generic | Prevention of skin and skin structure infections after a minor compromise in skin integrity such as minor burns or skin abrasion |
| bacitracin zinc, neomycin, polymyxin B sulfate ointment (Triple Antibiotic Ointment) | generic | Prevention of skin and skin structure infections, including wound management for skin abrasion and minor burn wound infection |
| bacitracin zinc, neomycin, polymyxin B sulfate, pramoxine ointment (Triple Antibiotic Plus Ointment) | generic | Prevention of skin and skin structure infections, including wound management for skin abrasion and minor burn wound infection |
| bacitracin zinc, polymyxin B ointment (Double Antibiotic Ointment) | generic | Prevention of skin and skin structure infections, including wound management of skin abrasion and minor burn wound infection |
| gentamicin 0.1% cream (Garamycin [®]) | generic | Treatment of minor bacterial skin infection including, folliculitis, furunculosis, impetigo, eczema, pyoderma gangrenosum, sycosis barbae, infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis, and infected excoriations |
| gentamicin 0.1% ointment (Garamycin [®]) | generic | Treatment of minor bacterial skin infection including, folliculitis, furunculosis, impetigo, eczema, pyoderma gangrenosum, sycosis barbae, infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis, and infected excoriations |
| mupirocin 2% cream (Bactroban [®]) | GlaxoSmithKline | Treatment of secondarily infected traumatic skin lesions (up to 10 cm in length or 100 cm ² in area) due to susceptible strains of <i>S. aureus</i> and <i>S. pyogenes</i> |
| mupirocin 2% ointment (Bactroban [®]) | generic | Treatment of impetigo due to <i>Staphylococcus aureus</i> and <i>Streptococcus pyogenes</i> |
| retapamulin 1% ointment (Altabax [™]) | GlaxoSmithKline | Treatment of impetigo due to <i>S. aureus</i> (methicillin-susceptible isolates only) and <i>S. pyogenes</i> |

Mupirocin calcium 2% ointment (Bactroban Nasal[®]) by GlaxoSmithKline is a paraffin-based formulation for intranasal use and is indicated in the eradication of nasal colonization with methicillin-resistant *S. aureus* (MRSA) in adult patients and healthcare workers.⁵

FDA-Approved Microorganism Indications⁶

| Drug | MRSA | MSSA | <i>Staphylococcus epidermidis</i> . | <i>Staphylococcus saprophyticus</i> | <i>Streptococcus pyogenes</i> | <i>Streptococcus sp.</i> | Positive <i>H. influenza</i> | Negative <i>H. influenza</i> | <i>Pseudomonas aeruginosa</i> |
|--|------|------|-------------------------------------|-------------------------------------|-------------------------------|--------------------------|------------------------------|------------------------------|-------------------------------|
| bacitracin ointment | | X | | | | X | | | |
| bacitracin zinc ointment | | X | | | | X | | | |
| bacitracin zinc, neomycin, polymyxin B sulfate ointment (Triple Antibiotic Ointment) | | X | | | | X | X | X | X |
| bacitracin zinc, neomycin, polymyxin B sulfate, pramoxine ointment (Triple Antibiotic Plus Ointment) | | X | | | | X | X | X | X |
| bacitracin zinc, polymyxin B ointment (Double Antibiotic Ointment) | | X | | | | X | X | X | X |
| gentamicin 0.1% cream (Garamycin) | | X | X | | X | | X | X | X |
| gentamicin 0.1% ointment (Garamycin) | | X | X | | X | | X | X | X |
| mupirocin 2% cream (Bactroban) | X | X | X | X | X | | | | |
| mupirocin 2% ointment (Bactroban) | X | X | X | X | X | | | | |
| retapamulin 1% ointment (Altabax) | | X | | | X | | | | |

MRSA: methicillin-resistant *S. aureus*

MSSA: methicillin-sensitive *S. aureus*

Overview

Skin and soft tissue bacterial infections are one of the most common issues with ambulatory care visits totaling approximately 14.2 million in 2005.⁷ Most infections can be treated outpatient although physicians should be on alert for signs and symptoms of more severe infections. Therefore, clinical assessment of the severity of the infection, diagnosis, and knowledge of pathogen-specific antibiotic resistance is important.⁸

Skin and soft tissue infections can be caused by many different bacteria. Most infections are due to gram-positive microbes such as *Staphylococcus aureus*, *Streptococcus viridans*, *Enterococcus faecalis*, and group A (*S. pyogenes*) and B streptococci. Though not as common, gram-negative skin and soft tissue infections can occur due to *Haemophilus influenza*, *Pasteurella multocida*, *Aeromonas* species, *Clostridium* species, *Vibrio* species, *Mycobacterium* species, *Capnocytophaga* species, *Pseudomonas* species, *Proteus* species, and other anaerobes.⁹ The most common skin infections are caused by *S. aureus*, *S. pyogenes*, or the normal skin flora.¹⁰ However, *S. aureus* and *S. pyogenes* also happen to show the most antibacterial resistance.¹¹

Patients who have compromised epidermis, poor hygiene, live in crowded conditions, have comorbidities, and have close contact with people having skin and soft tissue infections are at high risk of acquiring a skin and soft tissue infection themselves.^{12,13} Trauma to the epidermis exposes deeper tissue and allows for bacteria to enter the integumentary system. Other comorbidities which place patients at higher risk include eczema, psoriasis, superficial fungal infections, venous stasis, and lymphedema.¹⁴

Family physicians often treat patients with common skin infections such as impetigo.¹⁵ The Infectious Diseases Society of America (IDSA) 2005 practice guidelines for the diagnosis and management of skin and soft-tissue infections recommend mupirocin (Bactroban) ointment as the topical antibacterial drug of choice in the treatment of impetigo in infants two months and older and in adults.¹⁶ Mupirocin ointment has activity against *S. pyogenes* and both methicillin-sensitive *S. aureus* (MSSA) and methicillin-resistant *S. aureus* (MRSA), but some resistance has been reported.¹⁷ Other topical agents, such as bacitracin and neomycin, are considerably less effective topical treatments when compared to mupirocin ointment. Oral antibiotics, erythromycin, cephalexin, clindamycin, dicloxacillin, ciprofloxacin, levofloxacin, moxifloxacin, and ofloxacin are used to treat impetigo, and only effective for methicillin-sensitive *S. aureus* (MSSA).^{18,19,20} Topical therapy with mupirocin ointment is equivalent to oral systemic antimicrobials and may be used when lesions are limited in number. Patients who have numerous lesions or who are not responding to topical agents should receive oral antimicrobials effective against both *S. aureus* and *S. pyogenes*. Retapamulin (Altabax) was not available at the time of guideline development and publication.

Pharmacology^{21,22,23,24,25}

Mupirocin is an antibacterial that reversibly and specifically binds to bacterial isoleucyl transfer-RNA synthetase resulting in the inhibition of protein synthesis. Mupirocin is bactericidal at concentrations achieved by topical administration; however, the minimum bactericidal concentration (MBC) against relevant pathogens is generally eight-fold to thirty-fold higher than the minimum inhibitory concentration (MIC).

Retapamulin (Altabax) is the first in a new class of antibacterials, the pleuromutilins, which inhibit normal bacterial protein biosynthesis by binding at the unique site (L3) on the ribosomal

50S subunit. This prevents the formation of active 50S ribosomal subunits by inhibiting peptidyl transfer and blocking P-site interactions at this site. Retapamulin is bacteriostatic against *S. aureus* and *S. pyogenes* at the retapamulin *in vitro* minimum inhibitory concentration (MIC) for these organisms. At concentrations 1,000 times the *in vitro* MIC, retapamulin is bactericidal against these same organisms.

Bacitracin is a bacteriostatic against gram-positive and some gram negative bacteria and may also possess some bactericidal activity at certain concentrations. Bacitracin works by interfering with the mucopeptide transferring process and therefore prevents bacteria cell wall development.

Neomycin and gentamicin are aminoglycoside antibiotics with gram-positive and gram-negative bactericidal activity. Neomycin and gentamicin work by establishing irreversible binding to receptors present on the 30S ribosomal subunit of bacteria. The binding prevents the initiation complex between the bacterial messenger RNA and the ribosomal subunit which results in the misreading of the bacterial DNA and formation of nonfunctional proteins. As a result, bacteria containing these non-functional proteins die. Neomycin also inhibits DNA polymerase.

Polymyxin B is a bactericidal agent which binds to the cell membranes of gram-negative bacteria. Once bound, polymyxin destroys the bacterial cell membrane which results in cell membrane permeability and loss of metabolites.

Pharmacokinetics^{26,27,28 29,30}

Absorption of topically applied mupirocin is low. Data indicate more frequent occurrence of percutaneous absorption in children (90 percent of patients) than adults (44 percent of patients); however, mupirocin systemically absorbed is rapidly metabolized to the inactive metabolite, monic acid, which is renally excreted.

Systemic absorption following topical application of retapamulin to intact and abraded skin is low. Retapamulin (Altabax) is 94 percent protein bound. Retapamulin (Altabax) is metabolized by cytochrome (CYP) 3A4 hepatic enzymes by mono-oxygenation and di-oxygenation to multiple metabolites.

Bacitracin, neomycin, and polymyxin B have negligible systemic absorption after topical administration except when applied to large areas or long periods of time. Polymyxin B has little absorption even when applied to open wounds. However, systemic absorption has been reported when bacitracin, neomycin, or gentamicin have been applied to damaged epithelium. Gentamicin absorption across denuded skin had a rate of five percent but was not associated with systemic toxicity.

Contraindications/Warnings^{31,32,33,34,35}

Hypersensitivity to these agents or their components is considered a contraindication. These agents are for topical use only. They should not be used for ophthalmic, intranasal, oral, or intravaginal use. They should be discontinued should sensitization or severe local irritation occur, and super-infection occur.

Retapamulin (Altabax) should not be used in the absence of proven or strongly suspected bacterial infection.

Mupirocin (Bactroban) ointment contains polyethylene glycol (PEG) and should be avoided in conditions where absorption of large quantities of PEG is possible, especially if there is evidence of moderate to severe renal impairment; mupirocin (Bactroban) cream is not in a PEG base.

Bacitracin and neomycin should be used with caution in patients with damaged epithelium, high risk for altered epithelium (i.e. elderly, children less than two years, infants, and neonates), renal impairment, or renal failure due to increased systemic exposure and risk for adverse effects such as nephrotoxicity and irreversible ototoxicity. Bacitracin should not be used for serious burns, puncture wounds, deep wounds, or animal bites unless directed by a physician. When absorbed systemically, neomycin has been reported to cause ototoxicity; therefore, application to damaged epithelium is cautioned.

Drug Interactions^{36,37,38,39}

The effect of concurrent application of mupirocin ointment or cream and other drugs has not been studied.

Oral ketoconazole was shown to increase AUC and Cmax of retapamulin by 81 percent after topical application to abraded skin. Systemic absorption of retapamulin is low; therefore, interactions with other CYP 450 substrates are not expected. The effect of concurrent application of retapamulin and other topical agents to the same area of skin has not been studied.

If absorbed systemically, bacitracin, neomycin, and polymyxin B may cause nephrotoxicity and neurotoxicity. Caution should be used in patients taking additional medications with nephrotoxic or neurotoxic adverse effects.

Adverse Effects^{40,41,42,43,44}

| Drug | Application Site Irritation | Rash | Pruritus | Headache | Diarrhea | Nausea |
|--|-----------------------------|----------|----------|----------|----------|---------|
| bacitracin ointment | reported | reported | reported | nr | nr | nr |
| bacitracin zinc ointment | reported | reported | reported | nr | nr | nr |
| bacitracin zinc, neomycin, polymyxin B sulfate ointment (Triple Antibiotic Ointment) | reported | reported | reported | nr | nr | nr |
| bacitracin zinc, neomycin, polymyxin B sulfate, pramoxine ointment (Triple Antibiotic Plus Ointment) | reported | reported | reported | nr | nr | nr |
| bacitracin zinc, polymyxin B ointment (Double Antibiotic Ointment) | reported | reported | reported | nr | nr | nr |
| gentamicin 0.1% cream (Garamycin) | reported | reported | reported | nr | nr | nr |
| gentamicin 0.1% ointment (Garamycin) | reported | reported | reported | nr | nr | nr |
| mupirocin 2% cream (Bactroban) | < 1 | 1.1 | 2.4 | 1.7-3.6 | nr | 1.1-4.9 |
| mupirocin 2% ointment (Bactroban) | 1-1.5 | <1 | 1 | nr | nr | < 1 |
| retapamulin 1% ointment (Altabax) | 1.6-1.9 | nr | 1.5 | 1.2-2.0 | 1.4-1.7 | 1.2 |

Adverse effects are reported as a percentage. Adverse effects data are obtained from package inserts and are not meant to be comparative or all inclusive. nr = not reported.

Special Populations^{45,46,47,48,49}

Pediatrics

Safety and effectiveness of mupirocin (Bactroban) ointment and retapamulin (Altabax) ointment have been established in patients aged two months and older, and nine months and older, respectively. Mupirocin (Bactroban) cream has been FDA-approved in patients aged three months and older. Bacitracin, neomycin, and polymyxin B ointment have been FDA-approved in patients two years and older. Gentamicin cream and ointment have been FDA-approved for children over the age of one year.

Pregnancy

Mupirocin and retapamulin are Pregnancy Category B; bacitracin, neomycin, and polymyxin B, are Pregnancy Category C. Gentamicin is categorized by the manufacturer as Pregnancy Category D but Briggs' *Drugs in Pregnancy and Lactation* categorizes it as Pregnancy Category C.

Dosages^{50,51,52,53}

| Drug | Adult | Pediatrics | Availability |
|--|---|---|--|
| bacitracin ointment | Apply thin film two to three times daily (max five times daily). | Apply thin film two to three times daily (max five times daily). | 500 U/1 gm ointment: 1, 3.5, 4, 14, 15, 28, 30, 60, 113, 120, 144, 454 gm |
| bacitracin zinc ointment | Apply thin film two to three times daily (max five times daily). | Apply thin film two to three times daily (max five times daily). | 500 U/1 gm ointment: 1, 5, 14, 15, 28, 30, 120, 144, 454, 480 gm |
| bacitracin zinc, neomycin, polymyxin B sulfate ointment (Triple Antibiotic Ointment) | Apply thin film one to three times daily. | Apply thin film one to three times daily for patients two years and older. | bacitracin 400 U/ neomycin 3.5 mg/ polymyxin B 5000 U/1 gm ointment: 14, 15, 28, 30, 454 gm |
| bacitracin zinc, neomycin, polymyxin B sulfate, pramoxine ointment (Triple Antibiotic Plus Ointment) | Apply thin film one to three times daily. | Apply thin film one to three times daily for patients two years and older. | bacitracin 500 U/ neomycin 3.5 mg/ polymyxin B 10,000 U/ pramoxine 10 mg/1gm ointment: 14, 28, 30 gm |
| bacitracin zinc, polymyxin B ointment (Double Antibiotic Ointment) | Apply thin film one to three times daily. | Apply thin film one to three times daily. | bacitracin 500 U/ polymyxin B 10,000 U/ 1 gm ointment: 15, 28, 30 gm |
| gentamicin 0.1% cream (Garamycin) | Apply three to four times daily. | Apply three to four times daily for patients over one year old. | 0.1% cream: 15, 30 gm |
| gentamicin 0.1% ointment (Garamycin) | Apply three to four times daily. | Apply three to four times daily for patients over one year old. | 0.1% ointment: 15, 30 gm |
| mupirocin 2% cream (Bactroban) | Apply three times daily for ten days; re-evaluate after three to five days if no clinical response. | Apply three times daily for patients three months to 16 years old. | 2% cream: 15, 30 gm |
| mupirocin 2% ointment (Bactroban) | Apply three times daily; re-evaluate after three to five days if no clinical response. | Apply three times daily for patients two months to 16 years old. | 2% ointment: 0.9, 22 gm |
| retapamulin 1% ointment (Altabax) | Apply twice daily for five days; total treatment area should not exceed 100 cm ² . | For patients nine months to 17 years old: apply twice daily for five days; total treatment area should not exceed 2% body surface area. | 1% ointment: 5, 10, 15 gm |

Clinical Trials

Search Strategies

Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this class. Randomized, controlled trials studying agents within this class for the approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question and include follow-up (endpoint assessment) of at least 80 percent of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship/funding must be considered, the studies in this review have also been evaluated for validity and importance.

There are no published head to head trials comparing mupirocin and retapamulin (Altabax) in the treatment of impetigo. Due to the lack of studies, placebo-controlled trials have been included.

bacitracin ointment and white petrolatum

Bacitracin was compared to white petrolatum for evaluate the incidence of wound infection, allergic contact dermatitis, and overall healing characteristics.⁵⁴ The study was a double-blinded, randomized study conducted in an outpatient dermatology and tertiary referral advanced surgical clinic. A total of 922 patients entered the study with 884 (440 white petrolatum patients and 444 bacitracin patients) completing the four week study. Thirty-four patients with 38 wounds (20 white petrolatum patients with 22 wounds and 14 bacitracin patients with 16 wounds) developed pus, erythema, or tenderness at the wound. Cultures were performed on the 38 wounds and 18 cultures produced no growth, six cultures produced coagulase-negative *Staphylococcus* species, and 14 produced pathogenic bacteria. The 14 cultures were from 13 patients with nine (2.0%; 95% CI, 0.9% to 3.8%) patients being from the white petrolatum group and four patients (0.9%; 95% CI, 0.2% to 2.3%) being from the bacitracin group (95% for CI difference, -0.4% to 2.7%; $p=0.37$). Eight of the infections from the white petrolatum and zero from the bacitracin group were due to *Staphylococcus aureus* ($p=0.004$). No patients in the white petrolatum group developed allergic contact dermatitis versus four patients using bacitracin ($p=0.12$). The study found that patients using white petrolatum did not experience a significant difference in infection incidence compared to the bacitracin group. There was a higher rate of *S. aureus* infection in the white petrolatum group compared to the bacitracin group although this is to be expected since this is the most common bacterial to infect the skin, and bacitracin will eliminate it. Overall, the study concluded bacitracin and white petrolatum have an equally low infection rate, and there were no clinically significant differences in healing between the white petrolatum and bacitracin groups on day one ($p=0.98$), day seven ($p=0.86$), or day 28 ($p=0.28$) after the procedure.

bacitracin zinc ointment, bacitracin zinc/neomycin/polymyxin B ointment, sulfadiazine cream, and petrolatum ointment

A randomized, double-blind, placebo-controlled study was performed on 465 patients who presented to a military community hospital emergency department with a traumatic wound less than 12 hours old.⁵⁵ Thirty-nine patients were excluded from the study due to study protocol violations. There were more males in the study (n=300) compared to females (n=126) but the male-to-female ratios were similar between treatment groups. Patients were instructed to change the wound dressing and apply a blinded ointment to the wound every eight hours until the return visit to the emergency department for removal of stitches. The wound depths and locations were also not statistically significant, p=0.66 and p=0.89, respectively. Wound scrubbing (p=0.69) and wound debridement (p=0.67) were also not statistically different. The study concluded the wound infection rates for bacitracin zinc ointment (5.5 percent), bacitracin zinc/neomycin/polymyxin B ointment (4.5 percent), sulfadiazine cream (12.1 percent) were lower than petrolatum ointment (17.6 percent), p=0.0034, and that bacitracin zinc ointment and bacitracin zinc/neomycin/polymyxin B ointment had the lowest rate of wound infection.

mupirocin (Bactroban) cream and gentamicin cream

A multicenter, randomized, double-blind study was conducted to compare the effectiveness of daily gentamicin and mupirocin cream in the prevention of peritoneal dialysis (PD) site infections.⁵⁶ Mupirocin treats *S. aureus* PD infections but does not decrease *Pseudomonas aeruginosa* or other Gram-negative infections which often result in morbidity and even death in PD patients. The study included 133 patients (67 patients received gentamicin cream and 66 patients received mupirocin cream). The study found the time to first catheter infection was longer in patients using gentamicin compared to mupirocin (p=0.03). Likewise, the incident and prevalent patients had lower catheter infection rates with gentamicin compared to mupirocin and controlling for center and incident/prevalent status, only gentamicin had a lower catheter infection rate predictor (RR, 0.41; 95% CI, 0.22 to 0.78; p<0.007). Gentamicin also showed a lower incidence of Gram-negative (p=0.03) and Gram-positive (p<0.02) infections. The frequency of peritonitis was lower in patients using gentamicin (0.34/year) compared to mupirocin (0.52/year; p=0.03). Gentamicin use was also associated with a significant predictor of lower peritonitis rates when controlling for center and incident/prevalent patients (RR, 0.52; 95% CI, 0.29 to 0.93; p<0.03). Similarly gentamicin users also had a lower gram-negative peritonitis rate (p<0.05) when controlling for center and incident/prevalent status. In conclusion, researchers determined gentamicin cream was as effective as mupirocin in preventing *S. aureus* infections and gentamicin reduced *P. aeruginosa* and gram-negative catheter exit site infections and decreased the rate peritonitis by 35 percent.

mupirocin (Bactroban) ointment and placebo

The efficacy of mupirocin ointment in impetigo was assessed in a randomized, double-blind trial of adults and children aged two months and older.⁵⁷ Of the patients studied, 91 percent were between the ages of two months and 15 years. Patients received either mupirocin 2% ointment three times daily or placebo for eight to 12 days. Clinical efficacy rates at the end of therapy in the population were 71 percent for mupirocin (n=49) and 35 percent for placebo (n=51). Pathogen eradication rates were 94 percent and 62 percent, in the mupirocin and placebo groups, respectively. There were no adverse events reported for the mupirocin group.

mupirocin (Bactroban) ointment and oral erythromycin

Mupirocin ointment three times daily for eight days was compared to oral erythromycin 40 mg/kg/day, in a randomized open-label trial of patients five months to 13 years old with impetigo.⁵⁸ Patients were seen on days four to five of therapy, at end of therapy, and seven days after therapy had ended. At the first visit, 24 of 30 children in the mupirocin and 14 of 32 children in the erythromycin group were cured or had at least a 75 percent reduction in size of lesions. At the completion of the study, all 29 patients in the mupirocin group and 27 of the 29 patients in the erythromycin group were cured. Mild diarrhea developed in the erythromycin group. The study concluded that mupirocin appears to be safe and effective in the treatment of impetigo in children.

A prospective double-blind, randomized trial, compared topical mupirocin with oral erythromycin to determine the prevalence of erythromycin-resistant *S. aureus* strains in impetigo and whether an increased rate of failure of erythromycin was associated with such resistance.⁵⁹ A total of 102 patients between three months and 15.5 years old were enrolled and received erythromycin 50 mg/kg/day or mupirocin 2% ointment, plus respective placebos for seven days. *S. aureus* was cultured from 88 percent of patients of which 28 percent were erythromycin-resistant. In all cases *S. aureus* was sensitive to mupirocin. Only patients with erythromycin-resistant *S. aureus* strains had unfavorable courses compared with mupirocin (failure rate 47 percent versus two percent, respectively). Patients with erythromycin-susceptible *S. aureus* strains who received erythromycin had a failure rate of eight percent. In four patients, *S. aureus* strains initially susceptible to erythromycin became resistant during treatment. The study concluded that erythromycin-resistant *S. aureus* strains were commonly isolated from impetigo lesions in the study region.

mupirocin (Bactroban) cream and oral cephalexin

A randomized, double-blind, double-dummy, multicenter trial of 159 patients with secondarily infected eczema and a total skin infection rating scale score of eight or greater compared mupirocin 2% cream three times daily to oral cephalexin 250 mg four times daily for ten days.⁶⁰ Per protocol clinical success, defined partly as a patient with a response of improvement in the skin infection rating scale, was similar in both arms: 89 percent and 82 percent, in the mupirocin and cephalexin groups, respectively (95% CI, -8.4 to 22.5; p=0.29). Bacteriological success defined as eradication, improvement, or colonization of bacteria at end of therapy, was higher in the mupirocin group versus cephalexin, 50 percent versus 28 percent, respectively (p=0.005). Both drugs were well tolerated. Diarrhea and nausea were common adverse effects.

Two identical randomized, double-blind studies of 706 patients with secondarily infected wounds (small lacerations, abrasions, or sutured wounds) compared mupirocin 2% cream topically three times daily to oral cephalexin four times daily for ten days.⁶¹ Clinical success at follow-up was the same in the two groups, 95.1 percent versus 95.3 percent in the mupirocin cream and the cephalexin groups, respectively (95% CI, -4.0% to 3.6%; p=0.89). The intention-to-treat success rate was 83 percent in both groups. Bacteriologic success at follow-up was similar in the two groups: 96.9 percent in the mupirocin cream versus 98.9 percent in the cephalexin groups (95% CI, -6.0% to 2.0%; p=0.22). Adverse event profile was similar; however, more diarrhea in the cephalexin group was reported.

Mupirocin cream was compared to oral cephalexin in two randomized, double-blind, double-dummy studies of secondarily infected skin lesion studies.⁶² In the studies, 93 pediatric patients aged two weeks to 16 years old were randomized to mupirocin 2% cream three times daily or

oral cephalexin 250 mg four times daily for patients > 40 kg or 25 mg/kg/day oral suspension in four divided doses for patients ≤ 40 kg, for ten days. At follow-up (seven to 12 days after therapy), clinical efficacy was achieved in 97.7 percent and 93.9 percent, in mupirocin and cephalexin, respectively.

retapamulin (Altabax) and placebo

The safety and efficacy of retapamulin was evaluated in a randomized, double-blind, placebo-controlled, multicenter study enrolling 213 patients.^{63,64} A total of 210 adults and children aged nine months and older with impetigo (up to 100 cm² in total area- up to ten lesions- or a total body surface area not exceeding two percent), were randomized to retapamulin 1% ointment or placebo, applied twice daily for five days. Patients with underlying skin disease or skin trauma with evidence of secondary infections were excluded from the study. Most of the patients (78 percent) were less than 13 years old. Clinical success rates, defined as response of impetigo at seven days where no further antimicrobial treatment was required, were higher in the retapamulin group versus placebo, 85.6 percent versus 52.1 percent for the intent to treat population, respectively (95% CI, 20.5 to 46.5; p<0.0001). Pruritus at the application site was reported by six percent and one percent of the retapamulin and placebo groups, respectively.

Meta-analyses

A meta-analysis of 57 randomized controlled trials including 3,533 patients, studied comparisons of 20 oral and 18 topical treatments for impetigo.⁶⁵ Topical antibiotics had better cure rates than placebo (pooled OR 6.49, 95% CI, 3.93 to 10.73). There was no significant difference between topical mupirocin and topical fusidic acid (pooled OR of mupirocin versus fusidic acid 1.76, 95% CI, 0.69 to 2.16). Fusidic acid is not commercially available in the United States. Topical mupirocin had better cure rates compared to oral erythromycin (OR 1.22, 95% CI, 1.05 to 2.97). There were no significant differences in cure rates among other topical and oral antibiotics studied.

Another meta-analysis of 16 randomized controlled trials, including double-blinded and observer-blinded trials, indicated that topical antibiotics were more effective than placebo (OR 2.69, 95% CI, 1.49 to 4.86).⁶⁶ There was weak evidence favoring topical antibiotics over some oral antibiotics, such as erythromycin (OR 0.48, 95% CI, 0.23 to 1.00). There was no significant difference among the topical therapies, mupirocin and fusidic acid. (OR 1.76, 95% CI, 0.77 to 4.03).

Summary

Skin and soft tissue bacterial infections are a common problem seen in many clinical practices. Most skin and soft tissue infections can be managed on an outpatient basis and are easily treatable; however, physicians should observe for any signs or symptoms of severe infection. Several bacterial microorganisms can infect the skin and soft tissue, but the most common agents are *S. aureus* and group A (*S. pyogenes*) streptococci. In general, the selection of topical antibiotic agent will be dependent on the probable microorganism causing the infection.

The Infectious Diseases Society of America (IDSA) 2005 practice guidelines for the diagnosis and management of skin and soft-tissue infections recommend mupirocin (Bactroban) ointment as the topical antibacterial drug of choice in the treatment of impetigo in infants two months and older and adults.

Mupirocin (Bactroban) ointment and retapamulin (Altabax) have not been studied in head to head trials in the treatment of impetigo, so it is unclear if retapamulin (Altabax) is more effective than mupirocin. Retapamulin (Altabax) is not FDA-approved for use in infections caused by MRSA. At this time, retapamulin has only been compared to placebo. Retapamulin (Altabax) has an advantage in that its dosage regimen is twice daily versus that of mupirocin, which is three times daily; however, total treatment area for retapamulin should not exceed 100 cm² in adults or two percent of total body surface area (BSA) in children and adolescents. Retapamulin (Altabax) is an alternative to mupirocin ointment for the topical treatment of impetigo due to *S. aureus* (methicillin-susceptible isolates only) and *S. pyogenes*. Impetigo is usually a self-limiting skin infection, but resistance patterns should be taken into account in the choice of therapy.

Mupirocin (Bactroban) cream is FDA approved for the treatment of secondary infected traumatic skin lesions due to susceptible strains of *S. aureus* and *S. pyogenes*. It is not indicated for impetigo; however, mupirocin ointment is FDA approved for the treatment of impetigo due to *S. aureus* and *S. pyogenes*. Mupirocin (Bactroban) cream is not in a polyethylene glycol (PEG) base like mupirocin (Bactroban) ointment. PEG can be absorbed from open wounds and damaged skin therefore should be avoided in patients with moderate to severe renal impairment. Direct comparative trials of the cream and ointment formulations are lacking, and they are not considered interchangeable.

References

- ¹ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 3, 2010.
- ² Bactroban Ointment [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ³ Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.
- ⁴ Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ⁵ Bactroban Nasal Ointment [package insert]. Research Triangle Park, NC; GlaxoSmithKline; April 2009.
- ⁶ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 9, 2010.
- ⁷ McCaig LF, McDonald LC, Mandal S, et al. *Staphylococcus aureus* associated skin and soft tissue infections in ambulatory care. *Emerg Infect Dis.* 2006; 12:1715–23.
- ⁸ Stevens DL, Bisno AL, Chambers HF, et al. Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis.* 2005; 41(10):1373-1406.
- ⁹ Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published errata appear in *Clin Infect Dis.* 2005;41:1830 and 2006;42:1219]. *Clin Infect Dis.* 2005; 41:1373–406.
- ¹⁰ Hirschmann JV. Antimicrobial therapy for skin infections. *Cutis.* 2007; 79(6S):26-36.
- ¹¹ Stevens DL, Bisno AL, Chambers HF, et al. Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis.* 2005; 41(10):1373-1406.
- ¹² Stevens DL, Bisno AL, Chambers HF, et al; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections [published errata appear in *Clin Infect Dis.* 2005;41:1830 and 2006;42:1219]. *Clin Infect Dis.* 2005; 41:1373–406.
- ¹³ Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. *N Engl J Med.* 1996;334:240–5.
- ¹⁴ Timpler SJ and Brito MO. Bacterial Skin and Soft Tissue Infections. *Hospital Physician.* 2009; 45(3): 9-16, 26.
- ¹⁵ Stulberg, DL, Penrod, MA, and Blatny RA. Common Bacterial Skin Infections. *American Academy of Family Physicians.* 2002; 66(1): 119-124.
- ¹⁶ Stevens DL, Bisno AL, Chambers HF, et al. Infectious Diseases Society of America (IDSA). Practice guidelines for the diagnosis and management of skin and soft-tissue infections. *Clin Infect Dis.* 2005; 41(10):1373-1406.
- ¹⁷ Yun HJ, Lee SW, Yoon GM, et al. Prevalence and mechanisms of low and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. *J Antimicrob Chemother.* 2003; 51(3):619–623.
- ¹⁸ Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant *S. aureus* infections among patients in the emergency department. *N Engl J Med.* 2006; 355(7):666-674.
- ¹⁹ Grayson ML. The treatment triangle for Staphylococcal infections. *N Engl J Med.* 2006; 355(7):724-727.
- ²⁰ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 3, 2010.
- ²¹ Bactroban [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ²² Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ²³ DRUGDEX[®] System [Internet database]. Greenwood, CO: Thompson Micromedex. Updated periodically.
- ²⁴ Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.
- ²⁵ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 3, 2010.
- ²⁶ Bactroban Ointment [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ²⁷ Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ²⁸ Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.

- ²⁹ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 7, 2010
- ³⁰ Available at <http://www.thomsonhc.com>. Accessed March 7, 2010.
- ³¹ Bactroban [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ³² Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ³³ Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.
- ³⁴ Mupirocin. Available at www.clinicalpharmacology.com. Accessed on December 7, 2009.
- ³⁵ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 10, 2010.
- ³⁶ Bactroban [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ³⁷ Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ³⁸ Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.
- ³⁹ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 5, 2010.
- ⁴⁰ Available at <http://www.thomsonhc.com>. Accessed March 5, 2010.
- ⁴¹ Available at <http://online.factsandcomparisons.com>. Accessed March 17, 2010.
- ⁴² Bactroban [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ⁴³ Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.
- ⁴⁴ Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ⁴⁵ Bactroban [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ⁴⁶ Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ⁴⁷ Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.
- ⁴⁸ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 5, 2010.
- ⁴⁹ Available at <http://online.factsandcomparisons.com>. Accessed March 7, 2010.
- ⁵⁰ Available at: <http://www.clinicalpharmacology.com/>. Accessed March 5, 2010.
- ⁵¹ Bactroban [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ⁵² Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004
- ⁵³ Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ⁵⁴ Smack DP, Harrington AC, Dunn c, et al. Infection and Allergy Incidence in Ambulatory Surgery Patients Using White Petrolatum vs. Bacitracin Ointment. *JAMA*. 1996; 276(12): 972-977.
- ⁵⁵ Dire DJ, Coppola M, Dwyer DA, et al. Prospective Evaluation of Topical Antibiotics for Preventing Infections in Uncomplicated Soft-tissue Wounds Repaired in the ED. *Acad. Emerg. Med.* 1995; 2(4): 4-10.
- ⁵⁶ Bernardini J, Bender F, Florio T, et al. Randomized, Double-Blind Trial of Antibiotic Exit Site Cream for Prevention of Exit Site Infection in Peritoneal Dialysis Patients. *J Am Soc Nephrol.* 2005; 16: 539-545.
- ⁵⁷ Bactroban Ointment [package insert]. Research Triangle Park, NC; GlaxoSmithKline; November 2001.
- ⁵⁸ Goldfarb J, Crenshaw D, O'Horo J, et al. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo. *Antimicrob Agents Chemother.* 1988; 32(12):1780-1783.
- ⁵⁹ Dagan R, Bar-David Y. Double-blind study comparing erythromycin and mupirocin for treatment of impetigo in children: implications of a high prevalence of erythromycin-resistant *Staphylococcus aureus* strains. *Antimicrob Agents Chemother.* 1992; 36(2):287-290.
- ⁶⁰ Rist T, Parish LC, Capin LR, et al. A comparison of the efficacy and safety of mupirocin cream and cephalexin in the treatment of secondarily infected eczema. *Clin Exp Dermatol.* 2002; 27(1):14-20.
- ⁶¹ Kraus SJ, Eron LJ, Bottenfield GW, et al. Mupirocin cream is as effective as oral cephalexin in the treatment of secondarily infected wounds. *J Fam Pract.* 1998; 47(6):429-433.
- ⁶² Bactroban Cream [package insert]. Research Triangle Park, NC; GlaxoSmithKline; September 2004.
- ⁶³ Altabax [package insert]. Research Triangle Park, NC; GlaxoSmithKline; May 2009.
- ⁶⁴ Koning S, van der Wouden JC, Chosidow O, et al. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double-blind multicentre placebo-controlled trial. *Br J Dermatol.* 2008; 158(5):1077-82.
- ⁶⁵ Koning S, Verhagen AP, van Suijlekom-Smit LW, et al. Interventions for impetigo. *Cochrane Database Sys Rev.* 2004; (2):CD003261.
- ⁶⁶ George A, Rubin G. A systematic review and meta-analysis of treatments for impetigo. *Br J Gen Pract.* 2003; 53(491):480-487.